Methods For Treating or Preventing Inflammation and Periodontitis


Bone-loss-related diseases, such as periodontitis, are characterized by an imbalance between the formation and activity of osteoblasts and osteoclasts, leading to bone loss. There are several signaling pathways that participate in the osteoclastogenesis process. Finding inhibitors of these pathways and other osteoclastogenesis-related pathways may have an effect on bone-loss diseases.

Researchers at the National Cancer Institute (NCI), in collaboration with researchers at the University of Campinas, Brazil, have identified cinnamolyoxy-mammeisin (CNM), a 4-phenylcoumarin, which can be isolated from Brazilian geopropolis, as active against osteoclastogeneis pathways. CNM demonstrates anti-inflammatory activity and inhibition of oral bone loss in a mouse model of periodontitis. 



Potential Commercial Applications: Competitive Advantages:
  • Alternative to commercial antiresorptive agents
 
  • Lack of cytotoxicity


Development Stage:
Pre-clinical (in vivo)

Inventors:

John Beutler (NCI)  ➽ more inventions...

Marco Cunha ()  ➽ more inventions...

Pedro Rosalen ()  ➽ more inventions...

Marcelo Franchin ()  ➽ more inventions...


Intellectual Property:
Application No. 62/678,774

Publications:
Da Cunha M, et al. Effects of Cinnamoyloxy-mammeisin from Geopropolis on Osteoclast Differentiation and Porphyromonas gingivalis-Induced Periodontitis.  PMID 28570825
Franchin M, et al. Cinnamoyloxy-mammeisin Isolated from Geopropolis Attenuates Inflammatory Process by Inhibiting Cytokine Production: Involvement of MAPK, AP-1 and NF-kB.  PMID 27367493

Collaboration Opportunity:

Licensing and research collaboration


Licensing Contact:
John Hewes, Ph.D.
Email: John.Hewes@nih.gov
Phone: 240-276-5515

OTT Reference No: E-015-2018
Updated: Oct 12, 2018